The prevalence of earlier stages of CKD is even higher. Estimates for decreased GFR (corresponding to Stages 3 and 4) range from 0.8 to 8 million, depending on the cutoff values for serum creatinine (SCr) or estimated GFR. 1, 4 There may be as many as 20.3 million individuals with kidney damage, estimated by the presence of microalbuminuria or albuminuria (Stages 1 and 2). 1 Therapeutic interventions implemented early in the course of CKD have been demonstrated to be effective in delaying or preventing the adverse outcomes of chronic kidney disease. 5±7 The clinical action plan recommended by the NKF-K/DOQI clinical practice guideline focuses on: early detection, diagnosis, and treatment; slowing progression to kidney failure; detection and treatment of complications; preparation for and timely initiation of kidney replacement therapy; and diagnosis and treatment of cardiovascular disease and other comorbid conditions. The article by Winkelmayer et al. 8 focuses on selected comorbid conditions that could be tracked through administrative data. They demonstrate a low prevalence of preventive and screening tests among patients with CKD in the year prior to and in the year after the start of renal replacement therapy. They note that screening for cancers (breast and cervical among women, and prostate among men), and preventive measures for diabetes care (eye exam and hemoglobin A1C) were well below the rates for a general managed care population in the same geographic area. Potential explanations they put forth were physician inattentiveness, fatalism about patient outcomes, poor patient adherence to testing, and inadequate financial coverage for these tests. They conclude that increased testing may result in improved health outcomes among patients with end-stage renal disease.
Other reports have suggested that care of patients with CKD in the United States may be suboptimal. 9 We agree with the authors' discussion of possible causes of suboptimal care in the patients they studied. We suggest that the reported lack of comprehensive health care management offered to patients with CKD may be addressed by a more effective collaboration between the patients' primary care physicians and the specialists who participate in their care, following the action plan proposed in the NKF-K/DOQI guidelines.
EARLY DETECTION, DIAGNOSIS, AND TREATMENT
Detection of earlier stages of CKD, and classification of stages of CKD, can be done simply with routine laboratory testing: urine testing for albuminuria or proteinuria and estimation of GFR from serum creatinine. The NKF Guidelines for CKD recommend using a spot albumin-tocreatinine ratio, or albumin-specific dipsticks on a first morning void specimen to screen for CKD, and emphasize the need to estimate GFR from SCr, since SCr alone may misrepresent the level of kidney function, because it is related to muscle mass, dietary intake, and age. Initial diagnosis should focus on distinguishing among patients with diabetic kidney disease, nondiabetic kidney diseases, and diseases in kidney transplant recipients. Recent reviews and guidelines are helpful for the initial diagnosis and treatment of these conditions.
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ESTIMATING AND SLOWING PROGRESSION OF CHRONIC KIDNEY DISEASE IN ADULTS
In general, GFR should be estimated from serum creatinine at least yearly in patients with CKD and more often in patients with: GFR <60 mL/min/1.73 m 2 ; GFR decline 4 mL/min per year; risk factors for faster progression; ongoing treatment to slow progression; and exposure to risk factors for acute GFR decline. Numerous clinical trials have shown that blood pressure control, angiotensin-converting enzyme (ACE) inhibition, and glucose control in diabetics, are generally effective in retarding the development and progression of kidney disease; dietary protein restriction remains controversial.
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Treatments to slow the progression of chronic kidney disease in adults are summarized in Table 2 .
Adequate blood pressure control may be the single most important intervention in slowing the progression of renal disease; In patients with insulin-dependent diabetes mellitus (IDDM), intensive glycemic control can prevent or delay the development of microalbuminuria and the progression from microalbuminuria to albuminuria. 17, 19 Optimal blood glucose control is recommended in all diabetic patients even before the onset of microalbuminuria, and is recommended for patients with microalbuminuria, because it reduces the occurrence of nephropathy by 40% to 60%. 17, 30 It is not clear whether good glycemic control affects progression of nephropathy in its later stages. 14, 31 The American Diabetes Association has set forth a position statement with guidelines for the care of patients with diabetes mellitus (DM), 11 with specific attention to the complication of kidney disease. The reader can access complete guidelines for comprehensive information available on the internet at www.diabetes.org. The benefits of intensive glycemic control should be balanced with the risks associated with severe hypoglycemia, particularly among patients with advanced renal disease and the elderly. 29 The NKF-K/DOQI guidelines for CKD state that`t here is insufficient evidence to recommend for or against routine prescription of dietary protein restriction for the purpose of slowing the progression of chronic kidney disease.'' 1 The largest randomized controlled trial performed to date, the Modification of Diet in Renal 
CARDIOVASCULAR DISEASE RISK ASSESSMENT AND REDUCTION
In the last annual data report of the U.S. Renal Data System, the death rate from ischemic or atherosclerotic heart disease was 21.5 per 1,000 patient-years at risk. In addition, hospitalizations due to cardiovascular causes far outpace hospitalizations for other causes, accounting for 36% of all hospitalizations among ESRD patients.
2 Similarly, among patients with earlier stages of CKD at one center, cardiovascular disease (CVD) causes were the most common primary cause for hospitalizations. 35 Furthermore, CVD begins early in the course of CKD, and the prevalence increases with worsening kidney function: 30% to 45% of individuals with creatinine clearances <50 mL/ min, 36 and 74% of patients starting dialysis 37 are reported as having left ventricular hypertrophy. Among patients starting dialysis, 36% to 42% percent have had past myocardial infarction or coronary revascularization. 38 The NKF-K/DOQI guidelines recommend that patients with CKD should be considered in the``highest-risk group'' for CVD risk reduction. CVD and progression of CKD share many risk factors, and the relevant interventions target both of these conditions. However, few patients with CKD have been included in population-based epidemiologic studies of CVD or long-term randomized clinical trials. The NKF Task Force on Cardiovascular Disease in Chronic Renal Disease recommended risk factor reduction for``traditional'' risk factors based largely on extrapolation from the general population and evidence of safety and efficacy of interventions on risk factor levels in chronic kidney disease. It was the opinion of the CVD Task Force and the CKD Work Group that extrapolation from the general population to patients with chronic kidney disease is most appropriate for patients with Stages 1±4 CKD and less (but possibly still) appropriate for patients with kidney failure (Stage 5 CKD). A partial list of`t raditional'' CVD risk factors and risk factor reduction strategies that are potentially safe and effective for patients with CKD is shown in Table 3 .
DETECTING AND MANAGING COMPLICATIONS OF DECREASED GFR (<60ML/MIN/1.73 M 2 )
Many complications begin to occur once the GFR falls below 60 mL/min/1.73 m 2 , and can be prevented or delayed by early detection and treatment. High blood pressure is both a cause and a complication of CKD, and is associated with a faster rate of loss of kidney function, and development of CVD. Other complications include anemia, bone disease related to abnormal calcium and phosphorus metabolism, malnutrition or hypoalbuminemia, decreased functioning and well-being, and neuropathy. The presence of and severity of anemia is related to the duration and extent of kidney failure. Likewise, protein-energy malnutrition and abnormal calcium/phosphorus metabolism tend to be proportional to the degree of kidney function abnormality. Although objective findings of neuropathy are present in 15% to 85% of patients with varying degrees of CKD, it rarely becomes symptomatic unless the GFR is less than 12±20 mL/min/1.73 m 2 . Whether decreased functioning and well-being are directly related to level of kidney function or are affected by socioeconomic factors and associated comorbid conditions is unclear. Only anemia and malnutrition have been firmly associated with adverse outcomes.
39±47 Table 4 lists additional clinical evaluations that should be performed in adults with GFR <60 mL/min/1.73 m 2 to detect and manage complications of decreased kidney function.
CO-MANAGEMENT BY PRIMARY CARE PHYSICIANS AND SPECIALISTS
The evaluation and management of patients with CKD requires diagnosis and understanding of the related comorbid conditions, complications, and risks for loss of kidney function and development or worsening of CVD. Frequently the primary care provider will make the diagnosis of kidney disease, but may require the assistance of a nephrologist to define the cause if not immediately apparent. Given the high prevalence of CKD and the importance of early implementation of interventions to 
